title: Etoposide-based combination chemotherapy in malignant histiocytosis.
abstract: We investigated the responses of patients with malignant histiocytosis (MH) to the treatment of epotoside-based regimen. Of 11 evaluable cases, 9 (81.8%) achieved complete remission and 1 partial remission. 7 complete remission cases (77.7%) received only one therapeutic course. The side effects were mild and well-tolerated. We conclude that etoposide-containing regimen is highly effective and can be used as first-line treatment for MH and is worthy of further study.
authors.affiliation: Department of Hematology, Second Affiliated Hospital, Hebei Medical College, Shijiazhuang.
authors.forename: F R
authors.initials: FR
authors.lastname: Lin
authors.forename: E G
authors.initials: EG
authors.lastname: Yao
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003630:Daunorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage*; D005260:Female; D054747:Histiocytic Sarcoma / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D012074:Remission Induction
chemical_list: D005047:Etoposide; D011241:Prednisone; D003630:Daunorubicin